DSM, the Dutch chemical and pharmaceutical group, has posted net profits in the first quarter of 1994 of 83 million guilders ($45 million), compared with 6 million in the like, year-earlier period. The company said that the increase was achieved through a 9% increase in sales volumes and through lower fixed costs.
Sales in the quarter were 2.2 billion guilders, up 5% on the previous year's first quarter. The operating result was 112 million guilders, compared with 19 million guilders a year earlier. Earnings per share amounted to 2.31 guilders, compared with 0.17 guilders. DSM is confident that the second quarter will be similar to the first, but is not commenting on the full year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze